Stanley Kim, MD
Nephrology · Edison, NJNPI 1306850433
Payments from drug & device makers
Across 63 payments — averaging $23.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$155
- Sanofi-aventis U.S. LLC$151
- Aerin Medical Inc.$148
- Boehringer Ingelheim$148
- Novo Nordisk$125
- AbbVie$125
- plus $651 from 14 others
What the payments were for
- Food & beverage$1,47198%
- Education$332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 11 | $155 |
| Sanofi-aventis U.S. LLC | 3 | $151 |
| Aerin Medical Inc. | 1 | $148 |
| Boehringer Ingelheim | 3 | $148 |
| Novo Nordisk | 9 | $125 |
| AbbVie | 1 | $125 |
| Lilly USA, LLC | 11 | $124 |
| Radius Health, Inc. | 1 | $122 |
| Boston Scientific | 1 | $80 |
| Amgen(2 entities) | 5 | $78 |
| Johnson & Johnson | 4 | $49 |
| Mallinckrodt Enterprises LLC | 3 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Ceribell, Inc. | 1 | $25 |
| Merck | 2 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVAER STYLUS$148
- RHINAER STYLUS$148
- SOLIQUA 100/33$125
- DALVANCE$125
- Tymlos$122
- JARDIANCE$121
How this compares
$1,504 in reported general payments places this provider in the 55th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 363 | $481,057 |
| VascepaIcosapent Ethyl | 1,218 | $454,319 |
| JanuviaSitagliptin Phosphate | 566 | $453,462 |
| FarxigaDapagliflozin Propanediol | 351 | $290,612 |
| JardianceEmpagliflozin | 263 | $239,756 |
| LinzessLinaclotide | 226 | $165,630 |
| EliquisApixaban | 210 | $154,744 |
| ZenpepLipase/Protease/Amylase | 92 | $137,893 |
| Lidocaine | 777 | $131,946 |
| ProliaDenosumab | 76 | $121,620 |
| OzempicSemaglutide | 99 | $119,724 |
| RestasisCyclosporine | 138 | $114,653 |
| TrulicityDulaglutide | 46 | $89,990 |
| VelphoroSucroferric Oxyhydroxide | 42 | $89,373 |
| LokelmaSodium Zirconium Cyclosilicate | 65 | $76,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis, Restasis Multidose | $125 | $780,513753 claims |
| MerckJanuvia, Janumet, Janumet Xr | $24 | $536,227689 claims |
| AstraZenecaFarxiga, Lokelma | $155 | $367,477416 claims |
| Boehringer IngelheimJardiance, Tradjenta | $148 | $303,712349 claims |
| Aimmune Therapeutics, Inc.Zenpep | $15 | $137,89392 claims |
| AmgenProlia | $78 | $121,62076 claims |
| Novo NordiskOzempic | $125 | $119,72499 claims |
| Lilly USA, LLCTrulicity | $124 | $89,99046 claims |
| Johnson & JohnsonProcrit, Xarelto | $49 | $69,96145 claims |
| BayerKerendia | $17 | $56,42959 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Edison
- Robert CzyzewskiEdison$12K
- Samir SutariaEdison$10K
- Danny HaddadJersey City$1.7M
- Anup PatelWest Orange$1M
- Joshua KaplanNewark$509K
- Lawrence ByrdLivingston$338K
- Devang LodhaviaVoorhees$321K
- Jeffrey FeldmanUnion$315K
- Kenneth LissEatontown$271K
- Narender GoelJersey City$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.